Edgewise Therapeutics Inc (EWTX) — Cash Flow-to-Debt Ratio
Edgewise Therapeutics Inc (EWTX) has a Cash Flow-to-Debt Ratio of -1.68x as of March 2026, meaning its operating cash flow of $-42.54 Million could theoretically repay -2% of its total liabilities ($25.32 Million) in one year. See EWTX working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Edgewise Therapeutics Inc Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Edgewise Therapeutics Inc across 7 annual periods. Also explore net asset momentum of Edgewise Therapeutics Inc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Edgewise Therapeutics Inc (2019–2025)
Year-by-year debt coverage analysis for Edgewise Therapeutics Inc. For market capitalisation and broader financial context, see EWTX market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.74x | $-143.82 Million | $30.35 Million | ▼ -20.0% |
| 2024 | -3.95x | $-109.03 Million | $27.60 Million | ▲ +8.9% |
| 2023 | -4.34x | $-91.95 Million | $21.20 Million | ▼ -67.9% |
| 2022 | -2.58x | $-52.63 Million | $20.39 Million | ▲ +16.4% |
| 2021 | -3.09x | $-33.51 Million | $10.85 Million | ▼ -3372.6% |
| 2020 | -0.09x | $-14.63 Million | $164.56 Million | ▲ +59.9% |
| 2019 | -0.22x | $-9.17 Million | $41.39 Million | — |